2025
Identifying the Financial Toxicity Experiences of Childhood Cancer Survivors Through Partnership With a Community Organization Serving Rural and Minoritized Families
Benedict C, Bloomer K, Billman E, Smith M, Boynton H, Schapira L, Smith S. Identifying the Financial Toxicity Experiences of Childhood Cancer Survivors Through Partnership With a Community Organization Serving Rural and Minoritized Families. Psycho-Oncology 2025, 34: e70120. PMID: 40097346, DOI: 10.1002/pon.70120.Peer-Reviewed Original ResearchConceptsAYA survivors of childhood cancerSurvivors of childhood cancerChildhood cancerAYA survivorsFinancial toxicityAdolescent/young adultPerspectives of staff membersNon-English language preferenceStaff membersCancer support organizationsThematic analysis approachCommunity-based organizationsRural regionsParental employmentIndirect medical costsNeeds assessment studySemi-structured interviewsMedical visitsVulnerable populationsLanguage preferenceInsurance coverageMedical costsQualitative dataRural areasMinoritized familiesPsychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy
Belitzky E, Carvalho L, Taylor M, Ortiz C, Baum L, Fiellin D, Lustberg M. Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy. Cancer Medicine 2025, 14: e70586. PMID: 40052631, DOI: 10.1002/cam4.70586.Peer-Reviewed Original ResearchConceptsManagement of cancer painPsychological distressCancer painSymptom burdenUndertreatment of cancer painLevels of psychological distressFear of recurrenceSymptoms of cancerAssociated symptom burdenImprove pain managementMitigate psychological distressQuality of life challengesCancer-related painMitigate painAssociated psychological distressTreatment of cancer painNon-pharmacological approachesDiagnosis of cancerEfficacy of psychedelicsFear of deathLevel of evidenceCurrent level of evidenceBehavioral counselingCancer populationPain managementIntegrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population
Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.Peer-Reviewed Original ResearchConceptsGenomic dataEstimates of mutation ratesSomatic missense mutationsGenomic informationPopulation-level estimatesCancer patient populationMissense mutationsNon-epidemiologicallyCancer patientsMutation ratePathogenic mutationsCysteine residuesCancer epidemiologyMutation-specificMutation abundanceDrug targetsMutationsIntegrates epidemiologyAbundancePatient populationEpidemiologyGenomePopulationTargeted therapyResiduesUnderstanding oncologic emergencies and related emergency department visits and hospitalizations: a systematic review
Yilmaz S, Aryal K, King J, Bischof J, Hong A, Wood N, Gould Rothberg B, Hudson M, Heinert S, Wattana M, Coyne C, Reyes-Gibby C, Todd K, Lyman G, Klotz A, Abar B, Grudzen C, Bastani A, Baugh C, Henning D, Bernstein S, Rico J, Ryan R, Yeung S, Qdaisat A, Padela A, Madsen T, Liu R, Adler D. Understanding oncologic emergencies and related emergency department visits and hospitalizations: a systematic review. BMC Emergency Medicine 2025, 25: 40. PMID: 40045233, PMCID: PMC11883922, DOI: 10.1186/s12873-025-01183-2.Peer-Reviewed Original ResearchConceptsEmergency departmentEmergency visitsPredictors of ED usePeer-reviewed original research studiesSystematic reviewOncologic emergencyCancer incidence ratesCare delivery pathwaysGeriatric oncology researchManagement of oncologic emergenciesEmergency department visitsResultsThe search strategyTreatment side effectsOriginal research studiesCancer patientsVulnerable patient populationAcute careSingle-site studyWeb of ScienceCare venuesED useDepartment visitsHealth systemED visitsED presentationsProceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
Morris Z, Demaria S, Monjazeb A, Formenti S, Weichselbaum R, Welsh J, Enderling H, Schoenfeld J, Brody J, McGee H, Mondini M, Kent M, Young K, Galluzzi L, Karam S, Theelen W, Chang J, Huynh M, Daib A, Pitroda S, Chung C, Serre R, Grassberger C, Deng J, Sodji Q, Nguyen A, Patel R, Krebs S, Kalbasi A, Kerr C, Vanpouille-Box C, Vick L, Aguilera T, Ong I, Herrera F, Menon H, Smart D, Ahmed J, Gartrell R, Roland C, Fekrmandi F, Chakraborty B, Bent E, Berg T, Hutson A, Khleif S, Sikora A, Fong L. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology 2025, 26: e152-e170. PMID: 40049206, DOI: 10.1016/s1470-2045(24)00656-9.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseDelivery of radiotherapyTumor immune recognitionSelection of immunotherapyBiomarker-guided approachesNational Cancer Institute workshopClinical trial dataImmunotherapy combinationsClinical responseImprove patient outcomesPreclinical modelsPatient selectionRadiotherapyImmunotherapyClinical endpointsClinical dataClinical studiesImmune recognitionImmune responseImmune effectsAnimal studiesClinical translationPatient outcomesTrial dataNegative trialsSafety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Gambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, Spreafico A, Renouf D, Luen S, Galot R, de Spéville B, Calvo E, Naing A, Curdt S, Kolben T, Rossmann E, Tanos T, Smart K, Amann M, Xie Y, Xu L, Alcaide E, Städler N, Justies N, Boetsch C, Karanikas V, Schnetzler G, Rohrberg K. Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors. Cancer Research Communications 2025, 5: 422-432. PMID: 39983024, PMCID: PMC11891644, DOI: 10.1158/2767-9764.crc-24-0638.Peer-Reviewed Original ResearchConceptsRecommended phase II dosePhase II doseMaximum tolerated dosePhase I studyTreg depletionSolid tumorsII doseTolerated doseResistance to cancer immunotherapyRegulatory T-cell depletionImmunosuppressive regulatory T cellsEffector T cell functionAdvanced solid tumorsT-cell depletionRegulatory T cellsAnti-CD25 antibodyFrequent adverse eventsT cell functionDose-dependent depletionIL-2 signalingAtezolizumab combinationDeplete TregsTreg reductionDose escalationPeripheral TregsAn antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Schrank B, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin A, Jeong S, Antony A, Chang M, Kang M, Gallup T, Koong A, Li J, Yun K, Kim B, Jiang W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 2025, 6: 511-527. PMID: 40000910, DOI: 10.1038/s43018-025-00919-0.Peer-Reviewed Original ResearchConceptsAntibody-toxin conjugatesTumor cellsImmune recognition of tumor cellsEnhanced antigen cross-presentationRecognition of tumor cellsCancer cell phagocytosisTumor-derived antigensToxin listeriolysin OTumor-derived peptidesImproved animal survivalPromote immune recognitionCytosolic immune sensorsIntracellular bacterium Listeria monocytogenesTreatment in vivoTreating multiple cancersPhagocytosis checkpointsCheckpoint blockadeCancer immunotherapySignal CD47Listeriolysin OMetastatic breastMelanoma tumorsTherapeutic strategiesAnimal survivalCell phagocytosisLipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation
Liu J, Shen Y, Liu J, Xu D, Chang C, Wang J, Zhou J, Haffty B, Zhang L, Bargonetti J, De S, Hu W, Feng Z. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nature Communications 2025, 16: 1762. PMID: 39971971, PMCID: PMC11839913, DOI: 10.1038/s41467-025-57099-9.Peer-Reviewed Original ResearchConceptsGain-of-functionTumor suppressive function of p53Mutp53 accumulationAccumulate to high levelsFunction of p53Mutant p53 accumulationTumor suppressive functionMutant p53Subcutaneous xenograft tumor modelMutp53Promote tumorigenesisP53 accumulationPalmitoylationPotential therapeutic strategyXenograft tumor modelFASNTumor modelTumor organoidsTransgenic miceTherapeutic strategiesP53Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.Peer-Reviewed Original ResearchConceptsChemotherapy-induced nausea and vomitingEfficacy of cannabinoidsTHC:CBDMeta-analysisPrevention of chemotherapy-induced nausea and vomitingProphylaxis of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting controlControlled trialsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsNausea and vomitingChemotherapy-induced nauseaMethodsA literature searchCochrane Central RegisterComplete responseRandomized controlled trialsNo vomitingAdjunctive therapyRescue medicationAntiemetic regimensComposite endpointSubgroup analysisCannabinoidSecondary preventionDissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing
Castellanos-Rueda R, Wang K, Forster J, Driessen A, Frank J, Martínez M, Reddy S. Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing. Science Advances 2025, 11: eadp4008. PMID: 39951542, PMCID: PMC11827634, DOI: 10.1126/sciadv.adp4008.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorT-cell phenotypeT cell responsesT cell activationCAR T cell phenotypesCAR T-cell biologyModulate T cell responsesT cell persistenceCAR-T therapySingle-cell sequencingT cell functionT cell biologyCorrelated in vitroT therapyT cellsAntigen receptorClinical outcomesCD40 costimulationCancer treatmentPhenotypeSignaling domainMembrane-proximal domainCostimulationCD40Screening approachSafety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy
Bandla A, Wong R, Santhanakrishnan P, Magarajah G, Yee Y, Ng W, Ow S, Chan G, Choo J, Lim S, Wong A, Vijayan J, Paxman R, Lee Y, Hui F, Hairom Z, Ang E, Loprinzi C, Thakor N, Lee S, Kumarakulasinghe N, Lim J, Sundar R. Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy. Supportive Care In Cancer 2025, 33: 180. PMID: 39937296, PMCID: PMC11821790, DOI: 10.1007/s00520-024-08982-6.Peer-Reviewed Original ResearchConceptsChemotherapy-induced alopeciaChemotherapy-induced peripheral neuropathyScalp coolingHealthy volunteersCancer patientsPrevention of chemotherapy-induced alopeciaCIPN preventionPrevent chemotherapy-induced peripheral neuropathyEORTC QualityWeekly paclitaxel chemotherapyQoL scoresStandard-of-careBody temperature changesCryocompressionCore body temperature changesWeekly paclitaxelCTCAE v4.0Paclitaxel chemotherapyPhysician gradingLimbPatient toleranceAdverse eventsPeripheral neuropathyChemotherapyCryotherapyIntegration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology
Erbay M, Manubolu V, Stein-Merlob A, Ferencik M, Mamas M, Lopez-Mattei J, Baldassarre L, Budoff M, Yang E. Integration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology. Current Cardiology Reports 2025, 27: 51. PMID: 39932640, PMCID: PMC11814013, DOI: 10.1007/s11886-025-02206-x.Peer-Reviewed Original ResearchConceptsRadiation-induced cardiovascular diseaseCoronary artery diseaseCardiovascular diseaseCardiac massComputed tomographyArtery diseaseChest CT scans of patientsCT scans of patientsIncreased risk of CVDInvasive coronary angiographyRisk of cardiovascular diseaseRisk of complicationsScans of patientsCardiovascular computed tomographySeverity of cardiovascular diseaseNon-invasive imaging toolMonitoring of disease progressionManifestations of diseaseAsymptomatic patientsCardiac deteriorationIschemia evaluationCoronary angiographyPericardial diseaseCardiac changesRisk stratificationNanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Champiat S, Garralda E, Galvao V, Cassier P, Gomez-Roca C, Korakis I, Grell P, Naing A, LoRusso P, Mikyskova R, Podzimkova N, Reinis M, Ouali K, Schoenenberger A, Kiemle-Kallee J, Tillmanns S, Sachse R, Moebius U, Spisek R, Bechard D, Jelinkova L, Adkins I, Marabelle A. Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell Reports Medicine 2025, 6: 101967. PMID: 39933529, PMCID: PMC11866505, DOI: 10.1016/j.xcrm.2025.101967.Peer-Reviewed Original ResearchConceptsCD8<sup>+</sup> T cellsNatural killerT cellsAnti-programmed cell death protein 1Frequent treatment-emergent adverse eventsProportion of CD8<sup>+</sup> T cellsAnti-PD-1 pembrolizumabTreatment-emergent adverse eventsCell death protein 1Anti-PD-1Advanced/metastatic solid tumorsStimulated natural killerInjection site reactionsIL-15 receptorMouse tumor modelsPD-1NK cellsPeripheral bloodIL-15Safety profileSite reactionsSolid tumorsClinical efficacyAdverse eventsTumor modelPatient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy
Hertz D, Tanay M, Tofthagen C, Rossi E, Bernasconi D, Sheffield K, Carlson M, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M. Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2025, 33: 142. PMID: 39899120, DOI: 10.1007/s00520-025-09190-6.Peer-Reviewed Original ResearchConceptsSelf-reported peripheral neuropathyCross-sectional online surveyGuideline-recommended strategyEvidence of effectivenessNon-prescribed medicationTreating CIPNPurposeChemotherapy-induced peripheral neuropathyChemotherapy-induced peripheral neuropathyPeripheral neuropathyClinical teamStrategies patientsPrescription medicationsNeurotoxic chemotherapy treatmentMultinational AssociationDescriptive statisticsPrescribed medicationsSurvey participantsPrevention strategiesGuideline-recommendedTreatment of chemotherapy-induced peripheral neuropathyOnline surveyCIPNDebilitating toxicityImprove treatment outcomesMedicationMitochondrial succinate feeds T cell exhaustion in cancer
Galluzzi L, Guilbaud E, Garg A. Mitochondrial succinate feeds T cell exhaustion in cancer. Cancer Cell 2025, 43: 168-170. PMID: 39933894, DOI: 10.1016/j.ccell.2025.01.005.Peer-Reviewed Original ResearchDiagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosisCAR-T Entering a New "Phase": Improving CAR-T Function by Harnessing Phase Separation.
Su X. CAR-T Entering a New "Phase": Improving CAR-T Function by Harnessing Phase Separation. Cancer Research 2025, 85: 1011-1012. PMID: 39879116, PMCID: PMC11910263, DOI: 10.1158/0008-5472.can-25-0357.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorFunction of CAR T cellsCAR-T cellsNext-generation cell therapyT cell receptor complexCAR-T functionMouse xenograft modelCytotoxicity in vitroCAR-TT cellsAntigen receptorAntitumor effectCell therapyXenograft modelCoreceptor signalingImmune responseImmunological synapseReceptor complexBiomolecular condensatesCytoplasmic tailCoreceptorTherapyCD3ELiquid-liquid phase separationtRNA m1A modification regulates cholesterol biosynthesis to promote antitumor immunity of CD8+ T cells
Miao S, Li H, Song X, Liu Y, Wang G, Kan C, Ye Y, Liu R, Li H. tRNA m1A modification regulates cholesterol biosynthesis to promote antitumor immunity of CD8+ T cells. Journal Of Experimental Medicine 2025, 222: e20240559. PMID: 39873720, PMCID: PMC11774205, DOI: 10.1084/jem.20240559.Peer-Reviewed Original ResearchConceptsCD8+ T cellsT cellsTumor-killing functionTransfer RNARegulating cholesterol biosynthesisAntitumor immunityCapacity of CD8+ T cellsActivation of CD8+ T cellsCholesterol biosynthesisM1A modificationTumor-killing capacityAntitumor responseATP citrate lyaseCancer immunotherapyCD8Effector functionsMetabolic reprogrammingProtein translationBiosynthetic demandsCitrate lyaseIn vitro assaysIn vivoPosttranscriptional mechanismsRegulatory checkpointsBiosynthesisBayesian Modeling of Cancer Outcomes Using Genetic Variables Assisted by Pathological Imaging Data
Im Y, Li R, Ma S. Bayesian Modeling of Cancer Outcomes Using Genetic Variables Assisted by Pathological Imaging Data. Statistics In Medicine 2025, 44: e10350. PMID: 39840672, PMCID: PMC11774474, DOI: 10.1002/sim.10350.Peer-Reviewed Original ResearchBiological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Lopez de Rodas M, Villalba-Esparza M, Sanmamed M, Chen L, Rimm D, Schalper K. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nature Reviews Clinical Oncology 2025, 22: 163-181. PMID: 39820025, DOI: 10.1038/s41571-024-00984-x.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesImmune-checkpoint inhibitorsTumor-infiltrating lymphocyte subpopulationsClinical significance of tumor-infiltrating lymphocytesPredictive value of tumor-infiltrating lymphocytesSignificance of tumor-infiltrating lymphocytesStudy of tumor-infiltrating lymphocytesImmune-checkpoint inhibitor therapyImmune-mediated tumor eliminationEra of immunotherapyT cell dysfunctionBiomarkers of responseSolid tumor typesImmunotherapeutic approachesAntigen-reactiveTumor microenvironmentTumor typesClinical outcomesTumor eliminationClinical significanceSingle-cell transcriptomicsPredictive valueAnticancer mechanismClinical implicationsResistance mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply